Previous 10 | Next 10 |
SOUTH SAN FRANCISCO, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it is accepting proposals for the third annual Access to Excellent Care for Sickle Cell Patients (ACCEL) Grant Program , which provides fundi...
Global Blood Therapeutics, Inc. (GBT) Q4 2020 Results Earnings Conference Call February 24, 2021, 04:30 PM ET Company Participants Steven Immergut - Senior Vice President, Head of Corporate Communications and Investor Relations Ted Love - President and Chief Executive Officer Jeffrey Farrow -...
Image source: The Motley Fool. Global Blood Therapeutics (NASDAQ: GBT) Q4 2020 Earnings Call Feb 24, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Global Blood Therapeutics (GBT) Q4 2020 Earnings Call Transcript ...
Global Blood Therapeutics (GBT): Q4 GAAP EPS of -$1.00 misses by $0.04.Revenue of $41.3M (+1857.3% Y/Y) beats by $2.33M.CEO comment: “We continue to be confident in the long-term potential of Oxbryta and are well positioned to build on our strong fundamentals to enhance our commerciali...
Achieved Oxbryta ® (voxelotor) net revenues of $41.3 million in the fourth quarter and $123.8 million for full year 2020 Further established leadership in sickle cell disease (SCD) with data presentations on pipeline programs inclacumab and GBT021601 (GBT601) ...
[[ACA]], [[ACAD]], [[ADPT]], [[AGI]], [[AMED]], [[ANSS]], [[APA]], [[AWK]], [[BILI]], [[BKNG]], [[CCRN]], [[CDNA]], [[CHDN]], [[CNXN]], [[CW]], [[DDD]], [[DOOR]], [[DRH]], [[ECPG]], [[EPR]], [[ESI]], [[ESTC]], [[FATE]], [[FNF]], [[FTI]], [[GBT]], [[GEF]], [[GH]], [[HCC]], [[ICLR]], [[INGN]], ...
Global Blood Therapeutics (NASDAQ:GBT) is scheduled to announce Q4 earnings results on Wednesday, February 24th, after market close.The consensus EPS Estimate is -$0.97 (+39.0% Y/Y) and the consensus Revenue Estimate is $39.15M (+1755.5% Y/Y).Over the last 2 years, GBT has beaten EPS estimate...
SOUTH SAN FRANCISCO, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will report fourth quarter and full year 2020 financial results on Wednesday, February 24, 2021, after U.S. financial markets close. Manage...
SOUTH SAN FRANCISCO, Calif., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that an expanded access protocol (EAP) for Oxbryta ® (voxelotor) in pediatric patients with sickle cell disease (SCD) has been initiated and is cur...
The European Medicines Agency ((EMA)) has completed the validation of Global Blood Therapeutics’s (GBT) marketing application for Oxbryta (voxelotor) tablets seeking approval for hemolytic anemia in patients with sickle cell disease who are 12 years of age and older...
News, Short Squeeze, Breakout and More Instantly...
Global Blood Therapeutics Inc. Company Name:
GBT Stock Symbol:
NASDAQ Market:
Global Blood Therapeutics Inc. Website:
Guerbet to Spotlight the Novel New Drug Elucirem™ (gadopiclenol) injection at the 2022 Radiological Society of North America Scientific Assembly and Annual Meeting PR Newswire Join us at Booth #1711 Opportunity to learn about the recently US FDA-approved nov...
The healthcare industry is growing at an unprecedented rate, and healthcare stocks are poised to benefit from this growth. This is large because healthcare companies are developing innovative new treatments and technologies that are transforming the way we care for our health. As a resu...
NEW YORK, NY / ACCESSWIRE / September 22, 2022 / New York, New York-Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: EVO Payments...